A double-blind randomized controlled trial (RCT) investigated the efficacy of an inactivated proprietary strain. Bacillus subtilisRich in branched chain fatty acids (BCFA) (BG01-4) was used to treat self-reported FGID and placebo in 67 participants over a 4-week period.
The Australian and US authors concluded: “BG01-4 intake was well tolerated and reduced symptoms of constipation and associated gastrointestinal dysfunction.
“The significant improvement in overall GSRS suggests that BG01-4 has a potential role in alleviating certain symptoms such as dyspepsia, indigestion, and constipation.”
significance
FGIDs are a heterogeneous group of chronic diseases Characterized by persistent and recurrent gastrointestinal symptomsNo obvious structural or biochemical abnormalities that affect 25-40% of world population.
More than two-thirds of people with FGID He reportedly sought medical advice from his doctor.40% are regularly prescribed medication, and approx. A third person undergoes potentially unnecessary abdominal surgery.about their symptoms.
of Most common FGID conditionsThese include functional bowel disease, irritable bowel syndrome, as well as functional constipation, functional diarrhea, and functional bloating.
Current treatment strategiesSymptoms are directed by symptomatic treatment, but established treatments such as antibiotics and antidepressants inconsistent results.
Dietary restriction is a well-established treatment for some types of FGID; previous researchfound that one-third of adults with gastrointestinal illness restrict their diet, which impacts their mental health and overall quality of life.
Branched chain fatty acids (BCFA) are First recognized as an important nutrient for gastrointestinal (GI) healthIn relation to vernix, a white waxy substance that develops in late-stage human fetuses.
Vernix is rich in BCFA, accounting for approximately 30% of total fatty acids. BCFAs are rapidly taken up and incorporated into intestinal cell membranes. Place to soothe inflammatory response.
Bacillus subtilis(Bacillus subtilis) is the most well-studied Gram-positive microorganism, but reportedly Contains more than 50% BCFA in membrane lipids..
The researchers behind the current study conducted a large number of screens Bacillus subtilisUsing laboratory-scale cultured strains (unpublished), we identify a particularly rapidly growing strain (named “BG01-4”) containing high levels of BCFA.
BG01-4 was produced by fermentation, inactivated, and lyophilized. The authors reported that spores (5 × 109Inactivation of colony forming units) Bacillus subtilisBG01-4 is packaged in powder form and can be mixed with drinks or food to be taken as a probiotic.
Bacillus subtilishas been for a while Shown to help improve symptoms in people with constipation and diarrhea,and Reduced frequency and severity of abdominal bloating.
However, the authors point out that well-designed RCTs do investigate. Bacillus subtilisIts effectiveness on the overall quality of life of people with FGID has not been previously studied.
the study
The present study included healthy adults (n = 67) aged 18 to 75 years (all: 49.9 ± 14.1 years, men: n = 25 53.5 ± 12.9 years, women n = 42 48.8 ± 14.2 years old).
Eligibility for participation includes self-diagnosis of symptoms such as recurrent bloating, loose or watery stools, and/or functional constipation, criteria that must have started at least 6 months ago and at least 3 months ago Includes meeting the requirements.
Participants completed the intervention with BG01-4 (n = 34) or placebo (n = 33), consuming 1 sachet per day for 4 weeks.
Gastrointestinal Symptom Rating Scale (GSRS) surveys were conducted pre-intervention, 2 and 4 weeks after completion of the intervention.
The resulting data showed that at 4 weeks, constipation in the experimental group improved by 33% compared to placebo (15%).
Total GSRS and diarrhea were significantly improved in both the experimental and placebo groups (32%/26% and 20%/22%, respectively).
Dyspepsia improved at 4 weeks (32%) but not significantly compared to placebo (21%)p= 0.079).
However, exploratory analysis revealed a cluster of constipation (18% improvement; p< 0.001), indigestion (11% improvement; p= 0.04), indigestion (10% improvement; p= 0.04) was significantly improved in the intervention group compared to placebo.
However, the authors note that research was limited by the time of invention. Some probiotic research reportsThe intervention must be effective for at least 60 days to reach statistical significance, and others suggestThis period indicates that it is not long enough to see the full effect on gastrointestinal disorders.
The authors conclude that “long-term confirmatory studies of this intervention are warranted.”
Magazine: Nutrients
https://www.mdpi.com/2072-6643/15/21/4490
Bacillus subtilis (BG01-4TM) improves self-reported symptoms of constipation, dyspepsia, and dyspepsia: a phase 1/2A randomized controlled trial
Authors: Craig Patch, Alan J. Pearce, Mek Cheng, Ray Boyapati, J. Thomas Brenna